{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:16:46Z","timestamp":1784791006269,"version":"3.55.0"},"reference-count":30,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The efficacy of converting to oral fluoroquinolones after initial intravenous antibiotics for the treatment of acute pyelonephritis (APN) caused by the third\u2010generation cephalosporin resistant Enterobacteriaceae (3\u2010GCrEC) needs to be investigated. The objective was to compare the clinical and bacteriological outcome of oral prulifloxacin with intravenous ertapenem for the treatment of APN caused by 3\u2010GCrEC. A pilot, randomized controlled trial of patients with APN caused by 3\u2010GCrEC was conducted at two hospitals from August 2015 to December 2020. Any intravenous antimicrobial drug was initially permitted for empirical therapy. On day 4, adult patients (aged &gt;18\u2009years) with either non\u2010bacteremic or bacteremic APN were eligible for the study if their infection was caused by 3\u2010GCrEC susceptible to the study drugs. The patients were randomly assigned to receive either oral prulifloxacin or intravenous ertapenem. The total duration of antimicrobial therapy was 14\u2009days. Of the 21 enrolled patients, 11 were treated with prulifloxacin, and 10 were treated with ertapenem. At the test of cure visit, there was no statistically significant difference between the patients with overall clinical success who were treated with prulifloxacin (90.9%) and those treated with ertapenem (100%, <jats:italic>p<\/jats:italic>\u2009=\u20090.999). In addition, there was no statistically significant difference in microbiological eradication between the prulifloxacin and ertapenem groups (100% vs. 100%, <jats:italic>p<\/jats:italic>\u2009=\u20090.999). The converting to oral prulifloxacin after intravenous antibiotics therapy appears to be an alternative option for treatment of APN caused by 3\u2010GCrEC. A further large randomized controlled trial should be investigated.<\/jats:p>","DOI":"10.1111\/cts.13665","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T05:31:27Z","timestamp":1697693487000},"page":"2709-2718","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study"],"prefix":"10.1111","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7393-0901","authenticated-orcid":false,"given":"Apichot","family":"So\u2010Ngern","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy Siam University  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supunnee","family":"Jirajariyavej","sequence":"additional","affiliation":[{"name":"Department of Medicine Taksin Hospital  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huttaya","family":"Thuncharoon","sequence":"additional","affiliation":[{"name":"Microbiology Laboratory Taksin Hospital  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuttha","family":"Khunthupat","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Taksin Hospital  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerachai","family":"Chantarojanasiri","sequence":"additional","affiliation":[{"name":"Bhumirajanagarindra Kidney Institute  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6782-2939","authenticated-orcid":false,"given":"Preecha","family":"Montakantikul","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Faculty of Pharmacy Mahidol University  Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,28]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Guidelines on Urological Infections","author":"Grabe M","year":"2015"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3947\/ic.2013.45.1.22"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70041-0"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.4.657-686.2005"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2011.05.015"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.3.1.23"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00607-13"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw118"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr526"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2006.05.019"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00362-9"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.4.1.27"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-013-1891-z"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3616-3622.2001"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.12-0186"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1994.tb04007.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958002-00006"},{"key":"e_1_2_9_20_1","first-page":"61","article-title":"Comparative in\u00a0vitro activity of prulifloxacin against bacteria isolated from hospitalized patients at Siriraj Hospital","volume":"27","author":"Thamlikitkul V","year":"2010","journal-title":"J Infect Dis Antimicrob Agents"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S174506"},{"key":"e_1_2_9_22_1","unstructured":"Micromedex Healthcare Series [Internet database]. Greenwood Village Co: Thomson Micromedex.http:\/\/www.thomsonhc.com. Accessed January 12 2015."},{"key":"e_1_2_9_23_1","unstructured":"Clinical and Laboratory Standards Institute.Performance Standards for Antimicrobial Susceptibility Testing; Twenty\u2010Fifth Informational Supplement. CLSI document M100\u2010S25. Wayne PA: Clinical and Laboratory Standards Institute2015."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2017.05.005"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2502-x"},{"key":"e_1_2_9_26_1","doi-asserted-by":"crossref","first-page":"ii67","DOI":"10.1093\/jac\/dkh208","article-title":"Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double\u2010blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy","volume":"53","author":"Wells WG","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1086\/423000"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix606"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1086\/380645"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01509-06"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh204"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T12:34:11Z","timestamp":1705840451000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,28]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1111\/cts.13665"],"URL":"https:\/\/doi.org\/10.1111\/cts.13665","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,28]]},"assertion":[{"value":"2023-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}